BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 33378944)

  • 1. LncRNA TTN-AS1 intensifies sorafenib resistance in hepatocellular carcinoma by sponging miR-16-5p and upregulation of cyclin E1.
    Zhou Y; Huang Y; Dai T; Hua Z; Xu J; Lin Y; Han L; Yue X; Ho L; Lu J; Ai X
    Biomed Pharmacother; 2021 Jan; 133():111030. PubMed ID: 33378944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long noncoding RNA LEF1-AS1 acts as a microRNA-10a-5p regulator to enhance MSI1 expression and promote chemoresistance in hepatocellular carcinoma cells through activating AKT signaling pathway.
    Gao J; Dai C; Yu X; Yin XB; Zhou F
    J Cell Biochem; 2021 Jan; 122(1):86-99. PubMed ID: 32786108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA FOXD2-AS1 as a competitive endogenous RNA against miR-150-5p reverses resistance to sorafenib in hepatocellular carcinoma.
    Sui C; Dong Z; Yang C; Zhang M; Dai B; Geng L; Lu J; Yang J; Xu M
    J Cell Mol Med; 2019 Sep; 23(9):6024-6033. PubMed ID: 31210410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. lncRNA-POIR promotes epithelial-mesenchymal transition and suppresses sorafenib sensitivity simultaneously in hepatocellular carcinoma by sponging miR-182-5p.
    Chen BW; Zhou Y; Wei T; Wen L; Zhang YB; Shen SC; Zhang J; Ma T; Chen W; Ni L; Wang Y; Bai XL; Liang TB
    J Cell Biochem; 2021 Jan; 122(1):130-142. PubMed ID: 32951268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells.
    Li W; Dong X; He C; Tan G; Li Z; Zhai B; Feng J; Jiang X; Liu C; Jiang H; Sun X
    J Exp Clin Cancer Res; 2019 May; 38(1):183. PubMed ID: 31053148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of lncRNA SBF2-AS1 inhibits hepatocellular carcinoma proliferation and migration by regulating the miR-361-5p/TGF-β1 signaling pathway.
    Wu YH; Yu B; Chen WX; Ai X; Zhang W; Dong W; Shao YJ
    Aging (Albany NY); 2021 Aug; 13(15):19260-19271. PubMed ID: 34341185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of Long Non-coding RNA TTN-AS1 Inhibits Hepatocellular Carcinoma Progression by the MicroRNA-134/ITGB1 Axis.
    Huang Y; Chu P; Bao G
    Dig Dis Sci; 2021 Nov; 66(11):3916-3928. PubMed ID: 33387127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silencing
    Zhu Q; Ren H; Li X; Qian B; Fan S; Hu F; Xu L; Zhai B
    Aging (Albany NY); 2020 Nov; 12(22):22975-23003. PubMed ID: 33203790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long Noncoding RNA MALAT1 Contributes to Sorafenib Resistance by Targeting miR-140-5p/Aurora-A Signaling in Hepatocellular Carcinoma.
    Fan L; Huang X; Chen J; Zhang K; Gu YH; Sun J; Cui SY
    Mol Cancer Ther; 2020 May; 19(5):1197-1209. PubMed ID: 32220970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long non-coding RNA SBF2-AS1 promotes hepatocellular carcinoma progression through regulation of miR-140-5p-TGFBR1 pathway.
    Li Y; Liu G; Li X; Dong H; Xiao W; Lu S
    Biochem Biophys Res Commun; 2018 Sep; 503(4):2826-2832. PubMed ID: 30115383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long non-coding RNA TTN antisense RNA 1 facilitates hepatocellular carcinoma progression via regulating miR-139-5p/SPOCK1 axis.
    Zhu X; Jiang S; Wu Z; Liu T; Zhang W; Wu L; Xu L; Shao M
    Bioengineered; 2021 Dec; 12(1):578-588. PubMed ID: 33517826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long noncoding RNA UPK1A-AS1 indicates poor prognosis of hepatocellular carcinoma and promotes cell proliferation through interaction with EZH2.
    Zhang DY; Sun QC; Zou XJ; Song Y; Li WW; Guo ZQ; Liu SS; Liu L; Wu DH
    J Exp Clin Cancer Res; 2020 Oct; 39(1):229. PubMed ID: 33121524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m
    Chen YT; Xiang D; Zhao XY; Chu XY
    Hum Cell; 2021 Nov; 34(6):1800-1811. PubMed ID: 34374933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA DBH-AS1 facilitates the tumorigenesis of hepatocellular carcinoma by targeting miR-138 via FAK/Src/ERK pathway.
    Bao J; Chen X; Hou Y; Kang G; Li Q; Xu Y
    Biomed Pharmacother; 2018 Nov; 107():824-833. PubMed ID: 30142544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway.
    Song W; Zhang J; Xia Q; Sun M
    Cell Cycle; 2019 Nov; 18(22):3177-3188. PubMed ID: 31564201
    [No Abstract]   [Full Text] [Related]  

  • 17. Long Noncoding RNA TRIM52-AS1 Sponges miR-514a-5p to Facilitate Hepatocellular Carcinoma Progression Through Increasing MRPS18A.
    Zhou C; Chen Z; Peng C; Chen C; Li H
    Cancer Biother Radiopharm; 2021 Mar; 36(2):211-219. PubMed ID: 32391716
    [No Abstract]   [Full Text] [Related]  

  • 18. LncRNA DARS-AS1 aggravates the growth and metastasis of hepatocellular carcinoma via regulating the miR-3200-5p-Cytoskeleton associated protein 2 (CKAP2) axis.
    Feng Y; Wei G; Zhang L; Zhou H; Wang W; Guo P; Cheng C; Ji L; Cai Q; Feng Y; Tu H
    Bioengineered; 2021 Dec; 12(1):8217-8232. PubMed ID: 34596006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis.
    Wang Y; Yang L; Chen T; Liu X; Guo Y; Zhu Q; Tong X; Yang W; Xu Q; Huang D; Tu K
    Mol Cancer; 2019 Feb; 18(1):28. PubMed ID: 30782188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long noncoding RNA ZFPM2-AS1 acts as a miRNA sponge and promotes cell invasion through regulation of miR-139/GDF10 in hepatocellular carcinoma.
    He H; Wang Y; Ye P; Yi D; Cheng Y; Tang H; Zhu Z; Wang X; Jin S
    J Exp Clin Cancer Res; 2020 Aug; 39(1):159. PubMed ID: 32795316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.